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ABSTRACT 
Objective: Abies webbiana and Berberis aristata is an herbal plant that has several therapeutic effects. It also heals depression, grief, nervous 
stress and tension. In the present study we evaluated anti-depressant effect of ethanolic extract from Abies webbiana and Berberis aristata by 
using Forced Swimming Test (FST) and Tail Suspension Test (TST).  
Methods: Two doses of ethanolic extract of Abies webbiana and Berberis aristata (200 mg/kg and 400 mg/kg) was given orally. Immobility time 
were measured after 30 min after the dosing and compared with control group and Flouxetine (25mg/kg) as a standard group.  
Results: The ethanolic extract of BA and AW (400 mg/kg) was found to be effective and it exhibited activity similar to that of the conventional 
drug Flouxetine (25mg/kg) (p<0.001) whereas 200 mg/kg dose showed higher activity with significantly increased swimming time and 
suspension time and decreased immobility time than 400 mg/kg of ethanolic extracts and Flouxetine (25mg/kg).  
Conclusion: These results proposed 400 mg/kg of ethanolic extract was showed higher anti-depressant activity as compared to control which is 
similar to the standard. 
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Depression, a widespread incapacitating psychiatric ailment, 
imposes a substantial health burden on society 1. Affective 
disorder is characterized by a disturbance of mood 
associated with alteration in behavior, energy, appetite, 
sleep, and weight 2. According to the most accepted 
hypothesis of depression, the monoamine theory, patients 
with major depression have symptoms that are reflected 
changes in brain monoamine neurotransmitters, specifically 
norepinephrine (NE) and serotonin (5-HT) 3. Clinical data 
suggests that dopamine (DA) is also involved in the 
pathophysiology and treatment of depression 4. Medications 
such as tricyclic antidepressants (TCAs), selective serotonin 
reuptake inhibitors (SSRIs), monoamine oxidase inhibitors 
(MAOIs), specific serotonin-norepinephrine reuptake 
inhibitors (SNRIs), 5-HT2 receptor antagonists, and other 
heterocyclics are clinically employed for drug therapy 5. 
However, these drugs can impose a variety of side-effects 
including sedation, apathy, fatigue, sleep disturbance, 
cognitive impairment, and sexual dysfunction, and so forth. 
Hence, there remains a pressing need for new effective and 
better-tolerated antidepressants. 
The plant A. webbiana is well known under the vernaculars 
‘Himalayan silver fir’ in English, ‘Talispatra’ in Hindi and 
Bengali, ‘Talispatri’ in Tamil and ‘Badar’ in Kashmiri. In 
Indian traditional medicine and treatment it is used against 
cough, asthma and chronic bronchitis and various other 
diseases 6-8. The leaf juice of this plant is used in folklore to 
treat cough and asthma in the rural area of the Sikkim and 
Kashmir (India). The plant, a tall (maximum 60 m in height) 
evergreen tree, is found in the Himalayas from Kashmir to 
Assam at an altitude of 1600–4500 m in forests, largely 
located in a very humid region with heavy rain fall and dense 
mist. Leaves are variable in size, densely set in 2–4 ranks on 
stout branchlets, dark green, lustrous, coriaceous and persist 
up to 10 years 9. Daruharidra is one of the herbs mentioned 
in ancient scriptures of Ayurveda. Ayurvedic Pharmacopeia 
of India correlates Daruharidra to Berberis aristata DC of 
family Berberidaceae10, 11. The plant is native to the whole 
range of the Himalayas and also occurs in Nilgiri range in 
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southern India 12. Studies indicate that it is commonly used 
to treat eye infections, ENT infections, skin disease, 
menorrhagia, cholera, jaundice, wound healing and urinary 
tract infections, indigestion and vaginal disorders 13, 14. 
Owing to its high medicinal value, Daruharidra is of trade 
importance and an endemic species of conservation concern, 
which has quite high demand in herbal drug market. So to 
meet the need, herbal drug providers supply mixture of 
different Berberis species 15. B. aristata, reported to possess 
antimicrobial 16 antioxidant, anti-hyperglycemic 17, 
anti-amoebic 18 and wound-healing properties 19. B. asiatica 
possesses antimicrobial and anti-tumour effect. 
Our preliminary test indicated that ethanolic extract of Abies 
webbiana and Berberis aristata contained the largest amount 
of rhynchophylline derivatives. However, the 
antidepressant-like activity of Abies webbiana and Berberis 
aristata has not been investigated, which encouraged us to 
investigate the effects of on depression problems. In the 
present study, we aimed to investigate the effect of Abies 
webbiana and Berberis aristata in FST and TST in mice. The 
behavioral despair tasks have good predictive value for 
antidepressant potency in humans. Moreover, we 
investigated whether the effect of Abies webbiana and 
Berberis aristata in FST and TST is dependent on its 
interaction with the 5-HT, NE, and DA receptors, and the 
brain monoamine neurotransmitter concentration. 
MATERIALS AND METHODS  
Collection and extraction  
The aerial part of plant Abies webbiana and Berberis aristata 
was collected from the pattnamthitta, kerala in the month of 
December 2016. The plant was then authenticated by the 
joint director, the botanical survey of India. The aerial plant 
material were dried in shade and pulverized. The powder 
were passed through sieve no.40 and used for the extraction. 
The extract was prepared by the cold maceration method by 
using ethanol and water as solvent in the ratio of 30:70. 
Chloroform is used as preservative. This process was carried 
out with stirring the mass once daily for 14 days until the 
extraction was completed. After completion of extraction, the 
solvent was removed by distillation process the dark brown 
color residue was obtained.  
Animals  
Young adult Wister rat either sexes weighing 190-250 g 
were obtained from the animal house School of 
Pharmaceutical Sciences, Department of Pharmacology, 
IFTM University, Moradabad. They were caged in a room 
under standard laboratory conditions (temperature 23 ± 1°C, 
relative humidity 55% ± 5% and lighting 08:00 20:00 h). The 
animals were fed on a pelleted diet and water. The 
Institutional Animal Ethical Committee (IAEC) approved by 
the protocol of this study.  
Phytochemical screening  
The extract was screened for the presence of various 
phytochemical constituents employing standard screening 
test. The extracts were subjected to following chemical tests 




Acute oral toxicity studies 
Toxicity studies of extract were carried out in Swiss albino 
rats weighing between 25-30g. They were performed 
according to OECD guideline No. 423. Four groups of rats 
comprising three animals each were treated with 5, 50, 300 
and 2000mg/kg of the extract orally, via gastric catheter. The 
animals were then observed continuously for the first 4hrs 
for any behavioral changes and for mortality if any at the end 
of 72hrs. All four doses were found to be safe since no animal 
died even at the dose of 2000 mg/kg when administered 
orally and the animals did not showed any gross behavioral 
changes. 
Anti-Depressant screening 
Tail Suspension Test (TST) 
The test and standard compounds were administered p.o., 60 
minutes prior to testing. The rats were suspended on the 
edge of a shelf 58 cm above the table top by adhesive tape 
placed approx. 1 cm from the tip of tail. The duration of 
immobility was recorded for the period of 6 minutes by 
using stopwatch. After the initial period of vigorous motor 
activity, the rats would become still. Rats were considered 
immobile when they hang passively and completely 
motionless 22. 
Forced Swimming Test (FST):  
Either sex of rats were individually forced to swim in an 
open cylindrical container and container diameter is 10 cm, 
height is 25 cm. Cylindrical container filled by 19 cm of water 
at 25 ± 1°C. Either sex of rats were divided in four different 
groups. The first group assigned as control receiving only 
vehicle (NaCl 5 ml/ kg). The other three groups received 
acute dose based on acute toxicity studies of EEAW and 
EEBA (200 & 400 mg/kg). The Group II received standard 
drug Flouxetine (25mg/kg) dose is 30 mg/kg. The total 
duration of immobility was recorded during the last 4 min of 
the 6 min period. Rats were ceased struggling and remained 
floating motionless in the water, making only those 
movements necessary to keep its head above water when 
each mouse judged to be immobile. A decrease in the 
duration of immobility is indicative of an antidepressant like 
effect 21-26. 
Statistical analysis: Data were analyzed by Prism Install 
version software and presented as mean ± SEM. The 
statitical tests used were one-way analysis of variance 
(ANOVA) followed by tukey-kramer Multiple comparison 
test. The level of statical significant ranged from p<0.05 
top<0.001. 
RESULTS AND DISCUSSION  
The plant extract at the dose of 200 and 400 mg/kg were 
used for the in vitro antidepressant activity. The doses were 
selected based on the acute toxicity studies from the 
literature. The antidepressant effect of Abies webbiana and 
Berberis aristata (200 and 400 mg/kg) and Flouxetine 
(25mg/kg) were studied and observing the change in the 
duration of immobility by performing forced swim test and 
tail suspension test.  
The preliminary phytochemical screening indicated the 
presence of in Abies webbiana and Berberis aristata, have 
been shown to possess anti-depressant effect Flavonoids, 
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Table 1: Preliminary phytochemical constituents present in EEBA and EEAW Leaves 
Sr. No. Chemical Test Result of EEBA Result of EEAW 
1. Carbohydrate + + 
2. Protein + + 
3. Amino acid - + 
4.  Fat and Oil - - 
5. Steroids - - 
6. Volatile oil - - 
7. Glycoside + + 
8. Flavonoids + + 
9. Alkaloids - + 
10. Tannin  + + 
Positive (+), Negative (-) 
The effect of Abies webbiana and Berberis aristata extract 
may be due to the present of above said compounds. The 
extract was primarily subjected to phytochemical 
investigation and acute oral toxicity study. In Acute Oral 
Toxicity study, EEBA and EEAW did not show any lethal 
effect even up to the doses of 2000 mg/kg, p.o and complete 
absorption of drug through GIT was observed. The effect of 
EEBA and EEAW was investigated for its putative 
antidepressant activity by using various experimental 
models in rats viz. Tail Suspension test and Forced Swim 
test. Forced Swim test & Tail Suspension test are the most 
commonly used preliminary screening tests for 
characterizing potential antidepressant drugs. In this test 
Abies webbiana and Berberis aristata 200 and 400 mg/kg p.o 
produced significant reduction (p<0.05 and p<0.001 
respectively) in the immobility period when compared with 
that of control group animals that received only the vehicle. 
The extract (400 mg/kg) was found to be effective and it 
exhibited activity similar to that of the conventional drug 
Flouxetine (25mg/kg) (p<0.001) 27, 28 (table 2 and 3). 
  
Table 2: Tail suspension test 
Group Dose Immobility time in sec. 
I NS (10ml/kg) 122.33±12.972 
II Flouxetine (25mg/kg) 39.17±3.6*** 
IV EEAW (200mg/kg) 77.2 ±6.24* 
V EEAW (400mg/kg) 47.71±2.02** 
IV EEBA (200mg/kg) 82.24 ±6.24* 
V EEBA (400mg/kg) 49.41±4.02** 
 
Table 3: Forced swimming test 
Group Dose Immobility time in sec. 
I NS (10ml/kg) 152.33±10.972 
II Flouxetine (25mg/kg) 34.17±3.646*** 
IV EEAW (200mg/kg) 87.2 ±8.24** 
V EEAW (400mg/kg) 37.71±2.02*** 
IV EEBA (200mg/kg) 78.2 ±5.24** 
V EEBA (400mg/kg) 34.71±2.02*** 
 
 
The parameters observed in this model are immobility time 
of rats. Drugs which decrease immobility time leads to 
increase in the motor activity of rats which inhibit 
depression developed due to swimming and tail suspension 
of rats in these tests and offer protection against depression 
induced by these methods. In the present study, EEBA and 
EEAW (200 & 400 mg/kg, p.o) has shown a significant dose 
dependent activity i.e. increase in the dose of the drug 
proportional to decrease in the immobility time threshold 
and offers good percentage protection as compared to 
control group. Similarly, the standard drug Fluoxetine (25 
mg/kg, p.o) had significant percentage protection. Fluoxetine 
was selective serotonin reuptake inhibitor work on the 
serotonin balance by inhibiting a transporter that selectively 
pumps serotonin back into the neurons 29. 
CONCLUSION 
In the present study, EEBA and EEAW were evaluated by 
using various experimental models. EEDC at doses of 200 
mg/kg, p.o and 400 mg/kg, p.o showed significant increase 
in the motor activity of mice which elevate depressed mood 
by decreasing immobility time of mice in Forced Swim test 
and Tail Suspension test. From all the above findings, the 
present investigation suggests that the Ethanolic extract of 
Abies webbiana and Berberis aristata may possess 
antidepressant activity by inhibiting reuptake of Serotonin 
which acts through Serotonergic receptors (Gprotein 
coupled receptors) as mood elevator. Therefore lend 
pharmacological credence to the traditional use of this plant 
in the treatment of depression. However, an extensive 
Pharmacological study of this plant is required for complete 
understanding of the antidepressant activity of Ethanolic 
extract of Abies webbiana and Berberis aristata. Further 
investigation should be carried out to isolate and identify the 
chemical constituent which is responsible for its 
antidepressant activity. 
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